Bispecific antibodies (BsAbs) are emerging as an important novel class of
immunotherapeutic agents for the treatment of multiple myeloma (MM), and are set to be …

Bispecific antibodies, a novel immunotherapy with promising efficacy against multiple
myeloma, form immune synapses between T-cell surface marker CD3 and malignant cell …

ALLO-715 is a first-in-class, allogeneic, anti-BCMA CAR T cell therapy engineered to
abrogate graft-versus-host disease and minimize CAR T rejection. We evaluated escalating …

Bispecific T cell engagers (TCEs) have shown promise in the treatment of various cancers,
but the immunological mechanism and molecular determinants of primary and acquired …

The use of bispecific antibodies (BsAbs) in the treatment of relapsed/refractory multiple
myeloma (MM) is showing early promising overall response rates in heavily pretreated …

Background Iberdomide is a novel cereblon E3 ligase modulator with enhanced
tumouricidal and immune-stimulatory effects compared with immunomodulatory drugs. In …

Multiple myeloma is an incurable cancer characterized by the uncontrolled growth of
malignant plasma cells nurtured within a permissive bone marrow microenvironment. While …

Background Patients with relapsed/refractory multiple myeloma are at increased risk of
infection. Infections during treatment with teclistamab, the first B‐cell maturation antigen …

PURPOSE We present a phase I/II first-in-human trial evaluating the safety and efficacy of 50
mg and 200 mg doses of linvoseltamab, a B-cell maturation antigen× CD3 bispecific …

Simple Summary Multiple myeloma (MM) is a frequent hematological malignancy
characterized by the uncontrolled growth of clonal plasma cells, primarily in the bone …